AdAlta Secures Canadian Patent for AD-214, Strengthening Global IP Portfolio
AdAlta Limited (ASX: 1AD) has announced the granting of a composition of matter patent by the Canadian Intellectual Property Office for its lead anti-fibrotic product, AD-214. This patent secures protection for the product in Canada, completing the global protection of AD-214 across all major commercial markets.
The Canadian patent, numbered 2,973,317, is set to expire on 8 January 2036. AD-214 is now protected by composition of matter patents in key markets including the US, Canada, European Union, and Japan, as well as critical manufacturing regions like India and China.
This protection includes the i-body® sequence used in AD-214 and its pharmaceutical compositions, with a focus on applications in Idiopathic Pulmonary Fibrosis (IPF) and kidney fibrosis. The company has also applied for additional patents related to dosing and treatment methods, which could extend protection until 2043.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
AdAlta Secures Canadian Patent for AD-214, Strengthening Global IP Portfolio
AdAlta Limited (ASX: 1AD) has announced the granting of a composition of matter patent by the Canadian Intellectual Property Office for its lead anti-fibrotic product, AD-214. This patent secures protection for the product in Canada, completing the global protection of AD-214 across all major commercial markets.
The Canadian patent, numbered 2,973,317, is set to expire on 8 January 2036. AD-214 is now protected by composition of matter patents in key markets including the US, Canada, European Union, and Japan, as well as critical manufacturing regions like India and China.
This protection includes the i-body® sequence used in AD-214 and its pharmaceutical compositions, with a focus on applications in Idiopathic Pulmonary Fibrosis (IPF) and kidney fibrosis. The company has also applied for additional patents related to dosing and treatment methods, which could extend protection until 2043.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au